Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study
Identifieur interne : 001E40 ( Main/Exploration ); précédent : 001E39; suivant : 001E41Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study
Auteurs : J. Ring [Allemagne] ; A. Abraham [Inde] ; C. De Cuyper [Belgique] ; K. Kim [Corée du Sud] ; T. Langeland [Norvège] ; V. Parra [Argentine] ; P. Pigatto [Italie] ; T. Reunala [Finlande] ; R. Szczepanski [Allemagne] ; M. Möhrenschlager [Allemagne] ; M. Br Utigam [Allemagne] ; Ab Rossi [Suisse] ; E. Meents-Kopecky [Suisse] ; D. Schneider [Suisse]Source :
- Journal of the European Academy of Dermatology and Venereology [ 0926-9959 ] ; 2008-02.
English descriptors
- Teeft :
- Adverse events, Atopic, Atopic dermatitis, Atopic eczema, Authors jeadv, Baseline, Black columns, Concomitant, Concomitant steroids, Corticosteroid, Daily practice, Dermatol, Dermatology, Disease control, Disease improvement, Eczema, European academy, Facial, Facial involvement, Global satisfaction, Jeadv, Journal compilation, Mild pruritus, Moderate disease, Pimecrolimus, Pimecrolimus cream, Pimecrolimus cream ring, Pruritus, Pruritus relief, Severe disease, Steroid, Study drug, Topical steroids, Treatment success, Venereology, Venereology ring, White columns, Whole body.
Abstract
Background Pimecrolimus cream 1% has been shown to effectively control atopic eczema (AE) when applied twice daily from the first signs or symptoms of AE until clearance. Moreover, pimecrolimus cream 1% has a favourable safety profile, lacking topical corticosteroid‐related side‐effects such as skin atrophy, making it particularly useful to treat delicate body regions (e.g. the face). Objective The objective of this naturalistic study was to monitor the safety, tolerability and efficacy of pimecrolimus when used in the long‐term management of AE in a real‐life setting. Methods A multicentre, open‐label study was conducted in 2034 patients aged ≥ 3 months with mild to moderate AE for up to 12 months’ duration. Patients applied pimecrolimus cream twice daily, initiating treatment at first signs or symptoms of AE, continuing until clearance. Results Patients (n= 1847; 91%) completed 3 months of the study. Treatment success (clear or almost clear AE) after 3 months of treatment was observed on the whole body in 59% of patients and on the face in 81% of patients. Disease improvement of whole body and face was seen in 77% and 63% of patients, respectively. Pruritus was absent or mild in 79% of patients. Pimecrolimus cream was well tolerated throughout the study. Conclusion In a daily practice setting, pimecrolimus cream 1% effectively and safely controls AE.
Url:
DOI: 10.1111/j.1468-3083.2007.02368.x
Affiliations:
- Allemagne, Argentine, Belgique, Corée du Sud, Finlande, Inde, Italie, Norvège, Suisse
- Bavière, District de Haute-Bavière, Lombardie, Région capitale de Séoul, Østlandet
- Milan, Munich, Oslo, Séoul
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001619
- to stream Istex, to step Curation: 001546
- to stream Istex, to step Checkpoint: 000B75
- to stream Main, to step Merge: 001E42
- to stream Main, to step Curation: 001E40
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study</title><author><name sortKey="Ring, J" sort="Ring, J" uniqKey="Ring J" first="J" last="Ring">J. Ring</name></author><author><name sortKey="Abraham, A" sort="Abraham, A" uniqKey="Abraham A" first="A" last="Abraham">A. Abraham</name></author><author><name sortKey="De Cuyper, C" sort="De Cuyper, C" uniqKey="De Cuyper C" first="C" last="De Cuyper">C. De Cuyper</name></author><author><name sortKey="Kim, K" sort="Kim, K" uniqKey="Kim K" first="K" last="Kim">K. Kim</name></author><author><name sortKey="Langeland, T" sort="Langeland, T" uniqKey="Langeland T" first="T" last="Langeland">T. Langeland</name></author><author><name sortKey="Parra, V" sort="Parra, V" uniqKey="Parra V" first="V" last="Parra">V. Parra</name></author><author><name sortKey="Pigatto, P" sort="Pigatto, P" uniqKey="Pigatto P" first="P" last="Pigatto">P. Pigatto</name></author><author><name sortKey="Reunala, T" sort="Reunala, T" uniqKey="Reunala T" first="T" last="Reunala">T. Reunala</name></author><author><name sortKey="Szczepanski, R" sort="Szczepanski, R" uniqKey="Szczepanski R" first="R" last="Szczepanski">R. Szczepanski</name></author><author><name sortKey="Mohrenschlager, M" sort="Mohrenschlager, M" uniqKey="Mohrenschlager M" first="M" last="Möhrenschlager">M. Möhrenschlager</name></author><author><name sortKey="Br Utigam, M" sort="Br Utigam, M" uniqKey="Br Utigam M" first="M" last="Br Utigam">M. Br Utigam</name></author><author><name sortKey="Rossi, Ab" sort="Rossi, Ab" uniqKey="Rossi A" first="Ab" last="Rossi">Ab Rossi</name></author><author><name sortKey="Meents Opecky, E" sort="Meents Opecky, E" uniqKey="Meents Opecky E" first="E" last="Meents-Kopecky">E. Meents-Kopecky</name></author><author><name sortKey="Schneider, D" sort="Schneider, D" uniqKey="Schneider D" first="D" last="Schneider">D. Schneider</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A38082C7D903A4C27A77AF8FC844849353C79BB1</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1111/j.1468-3083.2007.02368.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-WK1H6LZZ-M/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001619</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001619</idno><idno type="wicri:Area/Istex/Curation">001546</idno><idno type="wicri:Area/Istex/Checkpoint">000B75</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000B75</idno><idno type="wicri:doubleKey">0926-9959:2008:Ring J:control:of:atopic</idno><idno type="wicri:Area/Main/Merge">001E42</idno><idno type="wicri:Area/Main/Curation">001E40</idno><idno type="wicri:Area/Main/Exploration">001E40</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study</title><author><name sortKey="Ring, J" sort="Ring, J" uniqKey="Ring J" first="J" last="Ring">J. Ring</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea> Division of Environmental Dermatology and Allergology GSF/TUM, Department of Dermatology and Allergy Biederstein, Technical University, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Allemagne</country></affiliation></author><author><name sortKey="Abraham, A" sort="Abraham, A" uniqKey="Abraham A" first="A" last="Abraham">A. Abraham</name><affiliation wicri:level="1"><country xml:lang="fr">Inde</country><wicri:regionArea>St. John's Medical College Hospital, Bangalore</wicri:regionArea><wicri:noRegion>Bangalore</wicri:noRegion></affiliation></author><author><name sortKey="De Cuyper, C" sort="De Cuyper, C" uniqKey="De Cuyper C" first="C" last="De Cuyper">C. De Cuyper</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea> Department of Dermatology, AZ Sint‐Jan General Hospital, Brugge</wicri:regionArea><wicri:noRegion>Brugge</wicri:noRegion></affiliation></author><author><name sortKey="Kim, K" sort="Kim, K" uniqKey="Kim K" first="K" last="Kim">K. Kim</name><affiliation wicri:level="3"><country xml:lang="fr">Corée du Sud</country><wicri:regionArea> Department of Dermatology, Seoul National University College of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Langeland, T" sort="Langeland, T" uniqKey="Langeland T" first="T" last="Langeland">T. Langeland</name><affiliation wicri:level="3"><country xml:lang="fr">Norvège</country><wicri:regionArea> Dermatological Clinic, Oslo</wicri:regionArea><placeName><settlement type="city">Oslo</settlement><region nuts="2">Østlandet</region></placeName></affiliation></author><author><name sortKey="Parra, V" sort="Parra, V" uniqKey="Parra V" first="V" last="Parra">V. Parra</name><affiliation wicri:level="1"><country xml:lang="fr">Argentine</country><wicri:regionArea> Hospital Lagomaggiore, Mendoza</wicri:regionArea><wicri:noRegion>Mendoza</wicri:noRegion></affiliation></author><author><name sortKey="Pigatto, P" sort="Pigatto, P" uniqKey="Pigatto P" first="P" last="Pigatto">P. Pigatto</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea> Fondazione IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena Milan and University of Milan, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Reunala, T" sort="Reunala, T" uniqKey="Reunala T" first="T" last="Reunala">T. Reunala</name><affiliation wicri:level="1"><country xml:lang="fr">Finlande</country><wicri:regionArea> Tampere University Hospital, Tampere</wicri:regionArea><wicri:noRegion>Tampere</wicri:noRegion></affiliation></author><author><name sortKey="Szczepanski, R" sort="Szczepanski, R" uniqKey="Szczepanski R" first="R" last="Szczepanski">R. Szczepanski</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea> Kinderhospital, Osnabrueck</wicri:regionArea><wicri:noRegion>Osnabrueck</wicri:noRegion><wicri:noRegion>Osnabrueck</wicri:noRegion></affiliation></author><author><name sortKey="Mohrenschlager, M" sort="Mohrenschlager, M" uniqKey="Mohrenschlager M" first="M" last="Möhrenschlager">M. Möhrenschlager</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea> Division of Environmental Dermatology and Allergology GSF/TUM, Department of Dermatology and Allergy Biederstein, Technical University, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name sortKey="Br Utigam, M" sort="Br Utigam, M" uniqKey="Br Utigam M" first="M" last="Br Utigam">M. Br Utigam</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Novartis Pharma GmbH, Nuremberg</wicri:regionArea><wicri:noRegion>Nuremberg</wicri:noRegion><wicri:noRegion>Nuremberg</wicri:noRegion></affiliation></author><author><name sortKey="Rossi, Ab" sort="Rossi, Ab" uniqKey="Rossi A" first="Ab" last="Rossi">Ab Rossi</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Pharma Novartis AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Meents Opecky, E" sort="Meents Opecky, E" uniqKey="Meents Opecky E" first="E" last="Meents-Kopecky">E. Meents-Kopecky</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Pharma Novartis AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Schneider, D" sort="Schneider, D" uniqKey="Schneider D" first="D" last="Schneider">D. Schneider</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Pharma Novartis AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of the European Academy of Dermatology and Venereology</title><title level="j" type="alt">JOURNAL OF EUROPEAN ACADEMY DERMATOLOGY VENEREOLOGY</title><idno type="ISSN">0926-9959</idno><idno type="eISSN">1468-3083</idno><imprint><biblScope unit="vol">22</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="195">195</biblScope><biblScope unit="page" to="203">203</biblScope><biblScope unit="page-count">9</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2008-02">2008-02</date></imprint><idno type="ISSN">0926-9959</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0926-9959</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adverse events</term><term>Atopic</term><term>Atopic dermatitis</term><term>Atopic eczema</term><term>Authors jeadv</term><term>Baseline</term><term>Black columns</term><term>Concomitant</term><term>Concomitant steroids</term><term>Corticosteroid</term><term>Daily practice</term><term>Dermatol</term><term>Dermatology</term><term>Disease control</term><term>Disease improvement</term><term>Eczema</term><term>European academy</term><term>Facial</term><term>Facial involvement</term><term>Global satisfaction</term><term>Jeadv</term><term>Journal compilation</term><term>Mild pruritus</term><term>Moderate disease</term><term>Pimecrolimus</term><term>Pimecrolimus cream</term><term>Pimecrolimus cream ring</term><term>Pruritus</term><term>Pruritus relief</term><term>Severe disease</term><term>Steroid</term><term>Study drug</term><term>Topical steroids</term><term>Treatment success</term><term>Venereology</term><term>Venereology ring</term><term>White columns</term><term>Whole body</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background Pimecrolimus cream 1% has been shown to effectively control atopic eczema (AE) when applied twice daily from the first signs or symptoms of AE until clearance. Moreover, pimecrolimus cream 1% has a favourable safety profile, lacking topical corticosteroid‐related side‐effects such as skin atrophy, making it particularly useful to treat delicate body regions (e.g. the face). Objective The objective of this naturalistic study was to monitor the safety, tolerability and efficacy of pimecrolimus when used in the long‐term management of AE in a real‐life setting. Methods A multicentre, open‐label study was conducted in 2034 patients aged ≥ 3 months with mild to moderate AE for up to 12 months’ duration. Patients applied pimecrolimus cream twice daily, initiating treatment at first signs or symptoms of AE, continuing until clearance. Results Patients (n= 1847; 91%) completed 3 months of the study. Treatment success (clear or almost clear AE) after 3 months of treatment was observed on the whole body in 59% of patients and on the face in 81% of patients. Disease improvement of whole body and face was seen in 77% and 63% of patients, respectively. Pruritus was absent or mild in 79% of patients. Pimecrolimus cream was well tolerated throughout the study. Conclusion In a daily practice setting, pimecrolimus cream 1% effectively and safely controls AE.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Argentine</li><li>Belgique</li><li>Corée du Sud</li><li>Finlande</li><li>Inde</li><li>Italie</li><li>Norvège</li><li>Suisse</li></country><region><li>Bavière</li><li>District de Haute-Bavière</li><li>Lombardie</li><li>Région capitale de Séoul</li><li>Østlandet</li></region><settlement><li>Milan</li><li>Munich</li><li>Oslo</li><li>Séoul</li></settlement></list><tree><country name="Allemagne"><region name="Bavière"><name sortKey="Ring, J" sort="Ring, J" uniqKey="Ring J" first="J" last="Ring">J. Ring</name></region><name sortKey="Br Utigam, M" sort="Br Utigam, M" uniqKey="Br Utigam M" first="M" last="Br Utigam">M. Br Utigam</name><name sortKey="Mohrenschlager, M" sort="Mohrenschlager, M" uniqKey="Mohrenschlager M" first="M" last="Möhrenschlager">M. Möhrenschlager</name><name sortKey="Ring, J" sort="Ring, J" uniqKey="Ring J" first="J" last="Ring">J. Ring</name><name sortKey="Szczepanski, R" sort="Szczepanski, R" uniqKey="Szczepanski R" first="R" last="Szczepanski">R. Szczepanski</name></country><country name="Inde"><noRegion><name sortKey="Abraham, A" sort="Abraham, A" uniqKey="Abraham A" first="A" last="Abraham">A. Abraham</name></noRegion></country><country name="Belgique"><noRegion><name sortKey="De Cuyper, C" sort="De Cuyper, C" uniqKey="De Cuyper C" first="C" last="De Cuyper">C. De Cuyper</name></noRegion></country><country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Kim, K" sort="Kim, K" uniqKey="Kim K" first="K" last="Kim">K. Kim</name></region></country><country name="Norvège"><region name="Østlandet"><name sortKey="Langeland, T" sort="Langeland, T" uniqKey="Langeland T" first="T" last="Langeland">T. Langeland</name></region></country><country name="Argentine"><noRegion><name sortKey="Parra, V" sort="Parra, V" uniqKey="Parra V" first="V" last="Parra">V. Parra</name></noRegion></country><country name="Italie"><region name="Lombardie"><name sortKey="Pigatto, P" sort="Pigatto, P" uniqKey="Pigatto P" first="P" last="Pigatto">P. Pigatto</name></region></country><country name="Finlande"><noRegion><name sortKey="Reunala, T" sort="Reunala, T" uniqKey="Reunala T" first="T" last="Reunala">T. Reunala</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Rossi, Ab" sort="Rossi, Ab" uniqKey="Rossi A" first="Ab" last="Rossi">Ab Rossi</name></noRegion><name sortKey="Meents Opecky, E" sort="Meents Opecky, E" uniqKey="Meents Opecky E" first="E" last="Meents-Kopecky">E. Meents-Kopecky</name><name sortKey="Schneider, D" sort="Schneider, D" uniqKey="Schneider D" first="D" last="Schneider">D. Schneider</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E40 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001E40 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A38082C7D903A4C27A77AF8FC844849353C79BB1
|texte= Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study
}}
| This area was generated with Dilib version V0.6.33. |  |